LUPUS NEPHRITIS - WHO CLASS IV
Clinical trials for LUPUS NEPHRITIS - WHO CLASS IV explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS - WHO CLASS IV trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS - WHO CLASS IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell therapy shows promise for tough lupus cases
Disease control OngoingThis early-stage study tests a new treatment called AB-101 for people with lupus nephritis or other hard-to-treat lupus. AB-101 uses donated natural killer cells to boost the body's ability to fight the disease. The study aims to see if this approach is safe and can help patients…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS IV
Phase: PHASE1 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control OngoingThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS IV
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control OngoingThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Matched conditions: LUPUS NEPHRITIS - WHO CLASS IV
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC